| Wang, Yang |
REDUCTION-I, NCT05582265: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 537 | RoW | Tislelizumab（neoadjuvant）, Cisplatin （neoadjuvant）, Nab-paclitaxel （neoadjuvant）, Surgical resection, Cisplatin（adjuvant）, Tislelizumab（adjuvant）, Radiation, Carboplatin (neoadjuvant）, Carboplatin (adjuvant） | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Shenzhen Sixth People's Hospital | Head and Neck Squamous Cell Carcinomas | 10/28 | 10/30 | | |
NCT05043311: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine. |
|
|
| Recruiting | 1/2 | 300 | RoW | SCTV01C, Placebo | Sinocelltech Ltd. | COVID-19, SARS-CoV-2 Infection | 06/22 | 01/23 | | |
NCT05043285: The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine. |
|
|
| Recruiting | 1/2 | 300 | RoW | SCTV01C, Placebo | Sinocelltech Ltd. | COVID-19, SARS-CoV-2 Infection | 06/22 | 01/23 | | |
EMPOWER, NCT04289480: Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 164 | RoW | ENTERPRISE 2 device | Medos International SARL, Johnson & Johnson Medical (Shanghai) Ltd. | Intracranial Aneurysm | 04/22 | 01/27 | | |
NCT05551884: Non-invasive Diagnosis of Portal Hypertension in Cirrhosis Based on Metabolomics Technology |
|
|
| Recruiting | N/A | 500 | RoW | Metabolites and HVPG | Hepatopancreatobiliary Surgery Institute of Gansu Province, The Third People's Hospital of Taiyuan, Lishui Country People's Hospital, Shenyang Sixth People's Hospital, QuFu People's Hospital, Shulan (Hangzhou) Hospital | Cirrhosis, Liver, Portal Hypertension | 09/23 | 09/23 | | |
NCT05962411: Effects of Dress by Adolescents on Electronic Cigarette Retailer Behaviors in China |
|
|
| Completed | N/A | 1089 | RoW | Dress in Professional Attire | Peking University, China Medical Board | Regulation Compliance, Electronic Nicotine Delivery Systems | 09/23 | 09/23 | | |
AMITY, NCT06436677: A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma |
|
|
| Recruiting | N/A | 100 | RoW | molecular subtype based treatment | Peking University First Hospital, Peking University Third Hospital, Peking University Cancer Hospital & Institute | Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma | 12/26 | 12/30 | | |
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome |
|
|
| Recruiting | N/A | 2000 | Europe, Japan, US, RoW | | Stanford University | Mycosis Fungoides, Non-Hodgkin's Lymphoma | 03/27 | 03/27 | | |
CORNERSTONE, NCT05316805: China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project |
|
|
| Recruiting | N/A | 100000 | RoW | | Peking University First Hospital | Atopic Dermatitis Eczema, Prurigo Nodularis | 12/31 | 12/31 | | |
| Recruiting | N/A | 3000 | RoW | | Peking University First Hospital | Primary Cutaneous Lymphoma | 08/32 | 08/32 | | |
| Akaza, Hideyuki |
| Enrolling by invitation | N/A | 20000 | Japan | | Japan Study Group of Prostate Cancer | Prostate Cancer | 03/19 | 03/26 | | |
| Miyagaki, Tomomitsu |
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome |
|
|
| Recruiting | N/A | 2000 | Europe, Japan, US, RoW | | Stanford University | Mycosis Fungoides, Non-Hodgkin's Lymphoma | 03/27 | 03/27 | | |
